文献速递淋巴瘤

TRIANGLE试验:年轻初治套细胞淋巴瘤含伊布替尼方案加用利妥昔单抗维持治疗

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
PubMed 文献 · J Clin Oncol · 2026-07-14

TRIANGLE试验二次分析纳入含伊布替尼方案(±ASCT)诱导后缓解的年轻初治套细胞淋巴瘤患者,比较加用利妥昔单抗维持(RM)与未加用的结局。RM延长无进展生存(I组4年PFS 85% vs 73%,A+I组90% vs 75%),但3-5级感染毒性更高。

要点

  • RM组3-5级感染毒性明显增加(I组34% vs 11%;A+I组41% vs 18%)。
  • 总生存有延长趋势,但未达统计学显著。

核心结论

  • 在年轻初治MCL患者中,含伊布替尼方案后加用利妥昔单抗维持可延长PFS,但增加感染毒性。

研究设计与样本

  • TRIANGLE试验的二次分析,纳入随机分配至含伊布替尼方案(不联合ASCT,I组)或联合ASCT(A+I组)且诱导/ASCT后缓解的患者。
  • I组274例、A+I组237例;RM根据国家和中心实践给予,I组61%、A+I组64%接受RM。
  • 采用逆概率治疗加权Kaplan-Meier曲线和log-rank检验比较PFS和OS。

主要发现

  • RM组OS有延长趋势。
  • RM组3-5级感染毒性风险更高:I组34% vs 11%;A+I组41% vs 18%。

关键数值与推荐

  • 3-5级感染毒性:I组RM 34% vs 无RM 11%;A+I组RM 41% vs 无RM 18%。

临床怎么用

  • 对年轻初治MCL患者,在含伊布替尼方案(±ASCT)诱导缓解后,可考虑加用利妥昔单抗维持以延长PFS。
  • 加用RM时需警惕3-5级感染毒性增加,加强感染监测与预防。

局限性

  • 为TRIANGLE试验的二次分析,RM非随机分配,依据国家和中心实践给予。
  • 采用逆概率治疗加权校正混杂,但可能存在未测量混杂。
  • OS差异仅为趋势,未报告统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The TRIANGLE trial established an ibrutinib-containing therapy without autologous stem-cell transplantation (ASCT) as the new standard for younger, treatment-naïve patients with mantle cell lymphoma (MCL). However, the benefit of rituximab maintenance (RM) within this novel standard is unclear. We investigated whether RM improves progression-free survival (PFS) and overall survival (OS) with acceptable toxicity when added to the experimental arms of TRIANGLE. This secondary analysis of TRIANGLE included patients randomly assigned to ibrutinib-containing therapy without (I) or with (A + I) ASCT who responded to induction/ASCT. RM was given per national and center practice. PFS and OS of patients with and without RM were compared with inverse probability of treatment weighted Kaplan-Meier curves and log-rank tests. Among responders after induction/ASCT (I: 274; A + I: 237), RM was given to 61% (I) and 64% (A + I). RM prolonged PFS in ibrutinib-containing treatment arms (I: log-rank test: P = .003, 4-year PFS probability RM v no RM, 85% v 73%; A + I: P < .001, 90% v 75%). There were trends toward prolonged OS in RM groups. RM groups were at higher risk of grade 3 to 5 infectious toxicity (I: 34% v 11%; A + I: 41% v 18%). Our findings support adding RM to BTK inhibitor treatments in younger, untreated patients with MCL to achieve prolonged remission.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ladetto M, Gutmair K, Tavarozzi R, et al. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. J Clin Oncol. 2026. PMID: 42447409. doi:10.1200/JCO-26-00705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。